903 results on '"Pospisilova, Sarka"'
Search Results
2. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 update
3. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia
4. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression
5. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
6. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
7. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
8. Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single‐cell RNA sequencing
9. Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
10. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis
11. RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia
12. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
13. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
14. Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene
15. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
16. The Minimal Dataset for Cancer of the 1+Million Genomes Initiative
17. Dynamic miRNA changes during the process of epileptogenesis in an infantile and adult-onset model
18. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience
19. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment‐naïve CLL patients.
20. Mobile retroelements induced by hypomethylating agents are restricted to transpose in myeloid malignancies
21. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
22. S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
23. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia
24. Primaquine hybrids as promising antimycobacterial and antimalarial agents
25. Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors
26. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase
27. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells
28. Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia
29. Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs
30. The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
31. ERIC recommendations for TP53mutation analysis in chronic lymphocytic leukemia—2024 update
32. Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia
33. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
34. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
35. Supplemental Table 4 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
36. Supplemental Table 5 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
37. Supplemental Table 1 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
38. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
39. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
40. Supplemental Table 3 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
41. Supplementary Table 1 from Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia
42. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
43. Supplemental Table 2 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
44. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
45. Supplemental Figure 1 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
46. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
47. The impact of standard chemotherapy on miRNA signature in plasma in AML patients
48. Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome
49. Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA)
50. Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.